

Home Health VNA IV Medication Clinical Fact Sheet

NOTE: THIS IS A PART B DRUG UNDER THE NEW HIT BENEFIT

Medicare patients may only be accepted under contract with New England Life Care and clinician must follow specific documentation instructions

IV Medication: Blinatumomab/Blincyto Risk Level: 1
Med Class: Chemotherapy

Common Uses: Cancer
Labs to Monitor: CBC c diff + Plts, BMP
Instructions/Precautions: Daily=wts, VS and Neuro checks, 2 pump in home and ensure extra medication available, no flush of medline 0.2 micron filter, Monitor for: changes in behavior, seizures, speech disorders, cytokine release such as chills, hypotension, wheezing

First Dose Allowed:

N

Central Line Only:

Y

IV Push:

N

Vesicant:

N

See Procedure Manual: Med Chemotherapeutic agents

**** Use specific interventions in HW to create the POC under IV Meds - IV Blincyto**

Notes: Only drugs listed as First Dose Allowed may be given in the home as a first dose and are considered for a first dose on a case by case basis by the IV Program Manager
The IV Manager and/or Clinical Director must be consulted before a first dose referral is accepted

Risk Levels: n/a = Routinely given; Clinician must be approved to administer IV medications
1= IV Program Mgr or Clinical Director approval before referral is accepted
2= IV Program Mgr notification; Clinicians must review Special Instructions